TY - JOUR
T1 - Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma
T2 - Current and Emerging Concepts
AU - Ruess, Dietrich A.
AU - Görgülü, Kivanc
AU - Wörmann, Sonja M.
AU - Algül, Hana
N1 - Publisher Copyright:
© 2017, Springer International Publishing Switzerland.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Pancreatic ductal adenocarcinoma is a devastating malignancy, which is the result of late diagnosis, aggressive disease, and a lack of effective treatment options. Thus, pancreatic ductal adenocarcinoma is projected to become the second leading cause of cancer-related death by 2030. This review summarizes recent developments of oncological therapy in the palliative setting of metastatic pancreatic ductal adenocarcinoma. It further compiles novel targets and therapeutic approaches as well as promising treatment combinations, which are presently in preclinical evaluation, covering several aspects of the hallmarks of cancer. Finally, challenges to the implementation of an individualized therapy approach in the context of precision medicine are discussed.
AB - Pancreatic ductal adenocarcinoma is a devastating malignancy, which is the result of late diagnosis, aggressive disease, and a lack of effective treatment options. Thus, pancreatic ductal adenocarcinoma is projected to become the second leading cause of cancer-related death by 2030. This review summarizes recent developments of oncological therapy in the palliative setting of metastatic pancreatic ductal adenocarcinoma. It further compiles novel targets and therapeutic approaches as well as promising treatment combinations, which are presently in preclinical evaluation, covering several aspects of the hallmarks of cancer. Finally, challenges to the implementation of an individualized therapy approach in the context of precision medicine are discussed.
UR - http://www.scopus.com/inward/record.url?scp=85016125586&partnerID=8YFLogxK
U2 - 10.1007/s40266-017-0453-y
DO - 10.1007/s40266-017-0453-y
M3 - Review article
C2 - 28349415
AN - SCOPUS:85016125586
SN - 1170-229X
VL - 34
SP - 331
EP - 357
JO - Drugs and Aging
JF - Drugs and Aging
IS - 5
ER -